Eprex 0.3 Ml 6000 Iu Janssen-Cilag

£456.00

Eprex 0.3 Ml 6000 Iu Janssen-Cilag is a recombinant human erythropoietin preparation designed for laboratory research applications examining hematopoietic growth factors and red blood cell production pathways in controlled experimental settings.

 

  • 30 days easy returns
  • Order yours before 2.30pm for same day dispatch
Eprex 0.3 Ml 6000 Iu Janssen-Cilag
Eprex 0.3 Ml 6000 Iu Janssen-Cilag
£456.00

[wpforms id=”1190″ title=”true” description=”Request a call back”]

Eprex Erythropoietin Research Overview

Eprex 0.3 Ml 6000 Iu Janssen-Cilag is a recombinant human erythropoietin (rHuEPO) preparation manufactured by Janssen-Cilag for in-vitro laboratory research. This glycoprotein hormone formulation enables researchers to investigate erythropoiesis mechanisms, hematopoietic stem cell differentiation, and cellular responses to hypoxic conditions in controlled experimental protocols. Scientists studying hematology, cell biology, and regenerative medicine can examine the molecular pathways governing red blood cell production using this research-grade erythropoietin preparation. The formulation provides standardised EPO concentrations for reproducible experimental outcomes across diverse research applications.

Research teams at Stroid UK Shop can access this pharmaceutical-grade erythropoietin alongside comprehensive erythropoietin research compounds for comparative studies. This preparation complements other research categories including selective androgen receptor modulators and research peptides for multifaceted biological investigations.

Laboratory Research Applications

Investigators utilise Eprex in cell culture studies examining erythroid progenitor cell proliferation, differentiation pathways, and EPO receptor signalling mechanisms. Research applications include analysing dose-response relationships in primary cell cultures, evaluating EPO’s cytoprotective effects against oxidative stress, and investigating the molecular mechanisms underlying erythropoietin-induced cellular responses. Scientists study EPO’s role in angiogenesis, neuroprotection, and tissue repair processes through controlled in-vitro experiments. The standardised 6000 IU concentration enables precise experimental design for dose-escalation studies and comparative analyses with other growth factors.

Advanced research protocols examine EPO’s interaction with hypoxia-inducible factors, JAK-STAT signalling pathways, and apoptosis regulation in various cell lines. Researchers investigate EPO’s potential therapeutic mechanisms through detailed molecular biology techniques, including gene expression analysis, protein phosphorylation studies, and cellular viability assessments under controlled laboratory conditions.

Product Specifications

Eprex 0.3 Ml 6000 Iu Technical Data
Parameter Specification
Product Name Eprex 0.3 Ml 6000 Iu
Manufacturer Janssen-Cilag
Concentration 6000 International Units per 0.3ml
Active Ingredient Recombinant Human Erythropoietin
Formulation Injectable solution
Storage Requirements 2-8°C, protect from light
Molecular Weight ~30.4 kDa
CAS Number Verify with supplier

Research Compliance Statement

Eprex 0.3 Ml 6000 Iu Janssen-Cilag is supplied exclusively for in-vitro laboratory research purposes. This product is not intended for human consumption, clinical use, or diagnostic applications. Researchers must maintain appropriate laboratory safety protocols and institutional approvals when handling this erythropoietin preparation. All experimental procedures should comply with relevant biosafety guidelines and institutional research ethics requirements.

Related